Management of Pelvic Metastases in Patients With Testicular Cancer

Joseph M. Jacob, Raul Mehan, Stephen D W Beck, K. Clinton Cary, Timothy Masterson, Richard Bihrle, Richard Foster

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Objective: To evaluate the clinicopathologic features and predictors of pelvic metastasis in patients with germ cell tumors. Methods: Between 1990 and 2009, 2722 patients undergoing retroperitoneal lymph node dissection (RPLND) were prospectively included in our institution's testis cancer database. Patients with pelvic disease were identified and clinicopathologic features were analyzed. Results: Of the 134 patients, 14.5% had a history of prior groin surgery. At the time of referral, 98% had received prior chemotherapy, 19.4% had undergone prior RPLND, and 24% presented as late relapse. Surgery consisted of pelvic excision alone in 37 (27.6%) and pelvic excision with primary RPLND in 2 (1.5%) or with postchemotherapy RPLND in 95 (70.9%). Median pelvic mass size was 6.5 cm. Pathology of pelvic disease revealed teratoma in 74 (55%), nonseminomatous germ cell tumor in 28 (21%), sarcoma in 8 (6%), and necrosis in 22 (16.5%). Patients with pelvic metastases had a statistically higher initial stage of presentation (P <.001) and had a higher incidence of prior groin surgeries (P <.001). Conclusion: Pelvic metastasis in testicular cancer is uncommon and can be a site of late relapse. These patients tend to present with high-volume retroperitoneal disease or a history of prior groin surgeries. Surgery is curative in most patients, and pelvic pathology was teratoma in more than half.

Original languageEnglish (US)
JournalUrology
DOIs
StateAccepted/In press - May 20 2016

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Management of Pelvic Metastases in Patients With Testicular Cancer'. Together they form a unique fingerprint.

  • Cite this